Skip to main content
. 2023 Oct 5;34(12):2039–2050. doi: 10.1681/ASN.0000000000000249

Table 1.

Demographics of the Renasight Clinical Application, Review, and Evaluation cohort

Characteristic Total Positive Casesa Negative
N 1623 338 1285
Age, yr
 Median (range) 55.0 (18.0–96.0) 48.0b (18.0–84.0) 57.0 (18.0–96.0)
Age groups, yr, n (%)
 18–39 315 (19.4) 98 (29.0)b 217 (16.9)
 40–64 913 (56.2) 182 (53.8) 731 (56.9)
 ≥65 393 (24.2) 57 (16.9)b 336 (26.1)
 Not reported 2 (0.1) 1 (0.3) 1 (0.1)
Sex at birth, n (%)
 Female 827 (51.0) 190 (56.2) 637 (49.6)
 Male 794 (48.9) 147 (43.5) 647 (50.4)
 Not reported 2 (0.1) 1 (0.3) 1 (0.1)
Race, n (%)
 Asian American 77 (4.7) 13 (3.8) 64 (5.0)
 Black/African American 251 (15.5) 74 (21.9)b 177 (13.8)
 American Indian/Alaska Native/Native Hawaiian/Pacific Islander 21 (1.3) 2 (0.6) 19 (1.5)
 White 1130 (69.6) 223 (66.0) 907 (70.6)
 Otherc/not reported 158 (9.7) 29 (8.6) 129 (10.0)
Ethnicity, n (%)
 Hispanic or Latino 334 (20.6) 58 (17.2) 276 (21.5)
 Not Hispanic or Latino 1257 (77.4) 274 (81.1) 983 (76.5)
 Unknown 32 (2.0) 6 (1.8) 26 (2.0)
Family history of CKD, n (%)
 No 1026 (63.2) 177 (52.4)b 849 (66.1)
 Yes 586 (36.1) 158 (46.7)b 428 (33.3)
 Not reported 11 (0.7) 3 (0.9) 8 (0.6)
a

False discovery rate correction for multiple testing comparing positive findings patients with negative findings patients.

b

P < 0.001.

c

Provided responses included: Mexican, Dominican, Ashkenazi Jewish, and Middle Eastern.